Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort. Prediction of oncogene mutation status in non-small cell ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for ...
Scientists at Bayer AG and Dana Farber Cancer Institute Inc. have identified EGFR (exon 20 insertion [Ex20Ins] mutant) and/or HER2 (erbB2) (Ex20Ins mutant) inhibitors reported to be useful for the ...
BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 ...
Please provide your email address to receive an email when new articles are posted on . Zongertinib conferred benefits in PFS and response as a first-line treatment option for HER2-mutant advanced non ...
Sevabertinib shows promise for advanced NSCLC with HER2 mutations, achieving a 72.1% objective response rate in the SOHO-01 trial. Patients with HER2 YVMA insertions exhibited a 90% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results